Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
gemcitabine + carboplatin + paclitaxel
- Development stage
- Unknown
- Lead developer
- Sidney Kimmel Comprehensive Cancer Center
- Modality
- Small Molecules
- Administration
- Intravenous
01
Overview
The combination of gemcitabine, carboplatin, and paclitaxel is a multi-agent chemotherapy regimen evaluated for the treatment of advanced non-small cell lung cancer (NSCLC). This specific sequential protocol, investigated by the Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins, involves the administration of gemcitabine and carboplatin followed by paclitaxel. Gemcitabine is a pyrimidine antimetabolite that inhibits DNA synthesis by inhibiting ribonucleotide reductase and incorporating into DNA. Carboplatin is a platinum-based antineoplastic agent that causes DNA cross-linking, thereby interfering with DNA replication and transcription. Paclitaxel is a taxane that stabilizes microtubules, preventing their depolymerization and leading to cell cycle arrest in the G2/M phase. This regimen was specifically designed to assess efficacy and tolerability in patients with advanced disease and poor performance status or significant comorbidities.
- Brand names
- GemzarParaplatinTaxol
- Other names
- Gemcitabine/Carboplatin/Paclitaxel regimenGemcitabine/Carboplatin followed by Paclitaxel
02
Targets
RNR (Ribonucleotide reductase)TUBB (Tubulin (alpha and beta subunits))DNA polymerase familyDNA
Beyond the preview
Go deeper on gemcitabine + carboplatin + paclitaxel.
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Indications & development
Full profile accessExplore development by indication, patient population, and geography.
- Indications
- Development status
- Countries
Licensing & deals
Full profile accessTrace asset ownership, licensing agreements, and commercial partnerships.
- Partners
- Deal terms
- Milestones
Patents & exclusivity
Full profile accessExplore the patent landscape and regulatory exclusivity around an asset.
- Patents
- Expiration dates
- Exclusivity
Competitive landscape
Full profile accessCompare development programs by target, modality, and indication.
- Competing assets
- Targets
- Development stage
Research & analysis
Full profile accessConnect source evidence and development news to your research questions.
- Publications
- News
- Analysis
Bring the full picture into focus.
See how Gosset can support your research on gemcitabine + carboplatin + paclitaxel.